$3.50
28.57% day before yesterday
Nasdaq, Dec 27, 10:18 pm CET
ISIN
IL0011651580
Symbol
PRFX
Sector
Industry

PainReform Ltd Stock price

$3.50
+0.75 27.27% 1M
-8.46 70.73% 6M
-62.50 94.70% YTD
-69.34 95.19% 1Y
-325.30 98.94% 3Y
-1,614.10 99.78% 5Y
-1,614.10 99.78% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.40 28.57%
ISIN
IL0011651580
Symbol
PRFX
Sector
Industry

Key metrics

Market capitalization $2.07m
Enterprise Value $-660.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.06
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-17.83m
Free Cash Flow (TTM) Free Cash Flow $-11.15m
Cash position $2.79m
EPS (TTM) EPS $-8.29
P/E forward negative
Short interest 9.08%
Show more

Is PainReform Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

PainReform Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast PainReform Ltd:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast PainReform Ltd:

Buy
100%

Financial data from PainReform Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
0% 0%
-
-0.02 -0.02
0% 0%
-
- Selling and Administrative Expenses 3.05 3.05
29% 29%
-
- Research and Development Expense 15 15
159% 159%
-
-18 -18
78% 78%
-
- Depreciation and Amortization 0.02 0.02
0% 0%
-
EBIT (Operating Income) EBIT -18 -18
78% 78%
-
Net Profit -18 -18
81% 81%
-

In millions USD.

Don't miss a Thing! We will send you all news about PainReform Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PainReform Ltd Stock News

Neutral
GlobeNewsWire
one day ago
TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.
Neutral
GlobeNewsWire
about one month ago
TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research ("Lotus"), for the Phase 3 clinical trial evaluati...
Neutral
GlobeNewsWire
about 2 months ago
TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has received a notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no long...
More PainReform Ltd News

Company Profile

PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

Head office Israel
CEO Ehud Geller
Employees 7
Founded 2007
Website www.painreform.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today